Revenue missed consensus by ~14% and declined YoY, but the operating loss improvement and reaffirmed guidance provide a floor. The $2.15M raise at $0.27/share (vs current price) is dilutive but extends runway. Watch for Q2 revenue acceleration from the dental ambassador and CompuFlo advisor programs to validate the double-digit growth outlook. The going-concern note limits upside until cash flow breakeven is demonstrated.
Price Chart
Executive Summary
Milestone Scientific reported Q1 2026 EPS of -$0.01, in line with consensus, and revenue of $2.16M, slightly below the $2.5M estimate. Operating loss narrowed to $828K from $2.0M a year ago due to a 30%+ reduction in expenses. Management reaffirmed 2026 revenue guidance of $9.8M-$10.2M (double-digit growth) and reiterated a target for cash flow breakeven in early 2027. The company also completed a $2.15M private placement post-quarter, improving liquidity, though a going-concern emphasis remains in the audit report.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.01, in line with consensus estimate of -$0.01
- Revenue $2.16M vs consensus $2.5M; down 3.2% YoY from $2.23M
- Operating loss narrowed to $828K from $2.0M YoY, driven by >30% expense reduction
- Medical segment revenue more than doubled YoY, but dental revenue was impacted by Middle East shipping delays
- Gross margin 72.3% vs 73.8% YoY, pressured by product mix, lower volume, and tariffs
- Cash $1.2M at quarter end; post-quarter $2.15M private placement (7.96M units at $0.27/unit) added $1.8M cash and reduced convertible debt by $351K
- Reaffirmed 2026 revenue guidance $9.8M-$10.2M, targeting double-digit growth
- Going-concern emphasis remains in audit report; management believes recent actions mitigate prior conditions
- Cash flow breakeven targeted for early 2027
Financial Impact
Revenue miss of ~$340K vs consensus; operating loss improvement of $1.17M YoY; $2.15M capital raise post-quarter
Risk Factors
- Going-concern uncertainty remains despite improved liquidity
- Revenue miss vs consensus and YoY decline signal execution headwinds
- Dilution from the $2.15M private placement (7.96M shares, ~10% of outstanding)
- Middle East conflict continues to disrupt booked orders
- Gross margin pressure from tariffs and product mix
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294794 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | EFFECT | $0.4100 $0.3671 | ▲ +10.46% | ▲ +12.41% | $0.3100 (+24.39%) |
Sep 18, 2026 5w ago | S-3/A | $0.3908 $0.4100 | ▲ +4.91% | ▲ +5.93% | $0.3100 (−20.68%) |
Aug 14, 2026 10w ago | Press Release | $0.4951 $0.4808 | ▼ −2.89% | ▼ −1.52% | $0.3100 (−37.39%) |
Jul 31, 2026 12w ago | 8-K | $0.3990 $0.4811 | ▲ +20.58% | ▲ +17.07% | $0.3100 (−22.31%) |
Jul 29, 2026 12w ago | 8-K | $0.3911 $0.4650 | ▲ +18.90% | ▲ +15.27% | $0.3100 (−20.74%) |
Jun 10, 2026 19w ago | EFFECT | $0.3899 $0.3400 | ▲ +12.80% | ▲ +16.23% | $0.3100 (+20.49%) |
Jun 2, 2026 20w ago | S-3 | $0.3900 $0.3900 | · 0.00% | ▼ −3.82% | $0.3100 (+20.51%) |
May 27, 2026 21w ago | Press Release | $0.3900 $0.3900 | · 0.00% | ▼ −1.21% | $0.3100 (−20.51%) |
May 14, 2026 23w ago | Press Release | $0.3400 $0.3900 | ▲ +14.71% | ▲ +15.42% | $0.3100 (−8.82%) |
May 6, 2026 24w ago | 8-K | $0.4700 $0.3500 | ▼ −25.53% | ▼ −27.04% | $0.3100 (−34.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers